Kallyope Stock
Kallyope is a biotechnology company focused on harnessing the gut-brain axis to develop innovative therapies for various health conditions. Kallyope aims to unlock the complex interactions between metabolic, neurological, and gastrointestinal systems to create effective treatments for diseases such as obesity, diabetes, and neurological disorders.
Sign up for SecondMarket™ to view the market and buy or sell Kallyope Stock
Buy + SellKallyope Funding
Sign up to gain insights into Kallyope funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the DataDate | Financing Round | Amount | Price per share* | Valuation* |
---|---|---|---|---|
Feb 15, 2022 | Series D | 236.00M | ||
Mar 18, 2020 | Series C | 112.50M | ||
Dec 05, 2018 | Series B | 20.76M | ||
Feb 22, 2018 | Series B | 66.15M | ||
Oct 27, 2016 | Series A | 16.00M | ||
Sep 30, 2015 | Series A | 12.05M |
See Kallyope Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Kallyope Stock Valuation + Share Prices
View real-time Tape D™ data on Kallyope stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get StartedKallyope Management Team
Chief Commercial Officer
Mark Myers
Director
Peter Hecht
Director
Fritz Lanman
Co-Founder, Solution Architect
Diego Netto
Co-founder, CEO, Director
Ross Lipson
Director
Scott Tobin
COO
Jason Snodgress
Director
Phil Venables
Director
Enrique Salem
Director
Kevin Diestel
Director
Hemant Taneja
Director
Mamoon Hamid
Director
Jerry Chen